The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance) Aggarwal, Rahul , Halabi, Susan , Kelly, William Kevin ... - - Cancer - 2013 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401
Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy Apolo, Andrea B. , Ostrovnaya, Irina , Halabi, Susan ... - - J. Natl. Cancer Inst - 2013 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90102
External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. Apolo, Andrea Borghese , Philips, George , Ostrovnaya, Irina ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - GU - CALGB-90102
Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903 Atkinson, Thomas M. , Halabi, Susan , Bennett, Antonia V. ... - - Pain Med - 2012 Manuscript - Primary - Primary - Health Outcome - CALGB-70903
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Bajorin, Dean F , Halabi, Susan ... - - Clin Genitourin Cancer - 2009 Manuscript - Primary - Primary - GU - CALGB-99903
Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy Beltran, Himisha , Wyatt, Alexander W , Chedgy, Edmund C ... - - Clin. Cancer Res. - 2017 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90203
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - - J. Clin. Oncol - 2017 Manuscript - Primary - Primary - GU - A031203
CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial. Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016 Abstract - Primary - Primary - GU - A031203
Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017 Abstract - Primary - Primary - GU - A031203
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - - Eur. J. Cancer - 2018 Manuscript - Secondary - Primary - GU - A031203
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study D'Amico, Anthony V. , Halabi, Susan , Tempany, Clare ... - - Int J Radiat Oncol Biol Phys - 2008 Manuscript - Secondary - Primary - GU - CALGB-9682
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). D'Amico, Anthony V , Halabi, Susan , Vollmer, Robin ... - - Urology - 2008 Manuscript - Secondary - Primary - GU - CALGB-159807 , CALGB-9682
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Dawson, Nancy A , Halabi, Susan , Ou, San-San , Biggs, David D ... - - Clin Genitourin Cancer - 2008 Manuscript - Primary - Primary - GU - CALGB-90004
Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer Garber, Judy E. , Halabi, Susan , Tolaney, Sara M. , Kaplan, Ellen ... - - J Natl Cancer Inst - 2010 Manuscript - Primary - Primary - Breast - CALGB-9872
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial George, Daniel J. , Hessel, Colin , Halabi, Susan ... - - Oncologist - 2019 Manuscript - Secondary - Primary - GU - A031203
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 9480. George, Daniel J , Halabi, Susan , Shepard, Timothy F , Sanford, Ben ... - - Clin. Cancer Res. - 2005 Manuscript - Primary - Primary - GU - INT-0159
Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance) George, Daniel.J. , Halabi, Susan , Nixon, Andrew B. , Starr, Mark D. ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary - Primary - Correl Sci NOS - CALGB-90206
Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial George, Daniel , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ASCO GU - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GU - A031203
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer Halabi, Susan , Kelly, William Kevin , Ma, Hua , Zhou, Haojin ... - - J. Clin. Oncol - 2016 Manuscript - Secondary-not-in-original - Comprehensive - GU - CALGB-90601
The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. Halabi, Susan , Kelly, William Kevin , Zhou, Haojin ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Meta-Analysis - GU - CALGB-90401 , S9916
Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer Halabi, Susan , Lin, Chen-Yen , Kelly, W. Kevin , Fizazi, Karim S. ... - - J. Clin. Oncol - 2014 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401
A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy Halabi, Susan , Lin, Chen-Yen , Small, Eric J. , Armstrong, Andrew J. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401
Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Halabi, Susan , Ou, San-San , Vogelzang, Nicholas J ... - - Cancer - 2007 Manuscript - Secondary-not-in-original - Meta-Analysis - GU - C9181 , C9182 , CALGB-90004 , CALGB-90006 , CALGB-9583 , CALGB-9680 , CALGB-9780 , CALGB-99813
Progression-Free Survival (PFS) as a Surrogate Endpoint of Overall Survival (OS) in Patients with Metastatic Renal Cell Carcinoma (mRCC) Halabi, Susan , Rini, Brian , Escudier, Bernard , Stadler, Walter M. ... - - Cancer - 2014 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90206
Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer Halabi, Susan , Vogelzang, Nicholas J. , Ou, San-San , Owzar, Kouros ... - - J Clin Oncol - 2009 Manuscript - Secondary-not-in-original - Comprehensive - GU - Comprehensive
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. Halabi, Susan , Vogelzang, Nicholas J , Kornblith, Alice B ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary-not-in-original - Comprehensive - GU - CALGB-9840 , C9181 , C9182
The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. Halabi, Susan , Vogelzang, Nicholas J , Ou, San-San ... - - J. Urol. - 2007 Manuscript - Secondary-not-in-original - Meta-Analysis - GU - C9181 , C9182 , CALGB-90004 , CALGB-9000 , CALGB-9583 , CALGB-9680 , CALGB-9780 , CALGB-99813 , INT-0159
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy Hertz, Daniel L. , Owzar, Kouros , Lessans, Sherrie , Wing, Claudia ... - - Clin. Cancer Res. - 2016 Manuscript - Primary - Primary - PPP - CALGB-60404 , CALGB-90401
A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). Hertz, Daniel Louis , Jiang, Chen , Owzar, Kouros , Halabi, Susan ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - PPP - CALGB-60404 , CALGB-90401
Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Hurwitz, Mark D , Halabi, Susan , Ou, San-San , McGinnis, Lamar S ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2008 Manuscript - Primary - Preliminary - GU - CALGB-99809
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401 Kelly, William Kevin , Halabi, Susan , Carducci, Michael ... - - J. Clin. Oncol - 2012 Manuscript - Primary - Primary - GU - CALGB-90401
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Kelly, William Kevin , Halabi, Susan , Elfiky, Aymen , Ou, San-San ... - - Cancer - 2008 Manuscript - Primary - Primary - GU - CALGB-99811
A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance) Kim, Hyung L. , Halabi, Susan , Li, Ping , Mayhew, Greg , Simko, Jeff ... - - EBioMedicine - 2015 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-150603 , CALGB-90206
A prognostic model for overall survival in patients with metastatic clear cell renal carcinoma: Results from CALGB 90206 (Alliance) Kim, Hyung L. , Halabi, Susan , Li, Ping , Mayhew, Greg , Simko, Jeff ... - AUA - J Urol - 2015 Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206
Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206 Kluger, Harriet M. , Halabi, Susan , Solomon, Nicole C ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - GU - CALGB-90206
Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) Li, Megan , Mulkey, Flora , Jiang, Chen , O’Neil, Bert H. ... - - Clin. Cancer Res. - 2018 Manuscript - Secondary-not-in-original - Meta-Analysis - PPP - CALGB-40502 , CALGB-80405 , CALGB-90401 , E5103
Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series Mohler, James L. , Halabi, Susan , Ryan, Stephen T. , Al-Daghmin, Ali ... - - Prostate Cancer Prostatic Dis. - 2019 Manuscript - Primary - Primary - GU - CALGB-9687
Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC) Morris, Michael J. , Heller, Glenn , Bryce, Alan , Armstrong, Andrew ... - ASCO - J Clin Oncol - 2019 Abstract - Primary - Primary - GU - A031201
Bevacizumab and risk of arterial and venous thromboembolism in metastatic castration-resistant prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance) Patel, Jai N. , Jiang, Chen , Hertz, Daniel L. , Mulkey, Flora A. ... - - Cancer - 2015 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401
A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance) Patel, Jai N. , Jiang, Chen , Owzar, Kouros , Hertz, Daniel L. ... - AACR - Cancer Res. - 2016 Abstract - Secondary-not-in-original - Primary - PPP - CALGB-90401
Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance). Patel, Jai Narendra , Jiang, Chen , Hertz, Daniel Louis ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401
A Phase II Study Of Estramustine, Docetaxel, And Bevacizumab In Men With Castrate Resistant Prostate Cancer: Results Of Cancer And Leukemia Group B (CALGB) 90006 Picus, Joel , Halabi, Susan , Kelly, W. Kevin ... - - Cancer - 2011 Manuscript - Primary - Primary - GU - CALGB-90006
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206 Rini, Brian I. , Halabi, Susan , Rosenberg, Jonathan E. ... - - J Clin Oncol - 2010 Manuscript - Primary - Primary - GU - CALGB-90206
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 Rini, Brian I. , Halabi, Susan , Rosenberg, Jonathan E. ... - - J Clin Oncol - 2008 Manuscript - Primary - Preliminary - GU - CALGB-90206
CALGB 90601 (Alliance): Randomized, double blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma Rosenberg, Jonathan , Ballman, Karla , Halabi, Susan , Watt, Colleen ... - ASCO - J Clin Oncol - 2019 Abstract - Primary - Primary - GU - CALGB-90601
Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. Ryan, Charles J , Dutta, Sandipan , Kelly, William K ... - - Clin Genitourin Cancer - 2019 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401
Serum Androgens and Survival in metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Docetaxel and Prednisone: Results from CALGB 90401 (Alliance) Ryan, Charles J , Dutta, Sandipan , Kelly, William K ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401
Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC) Ryan, Charles J , Dutta, Sandipan , Kelly, William K , Russell, Carly ... - - Prostate Cancer Prostatic Dis. - 2020 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-90401
Decline in serumandrogens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: results from CALGB 90401 (Alliance) Ryan, Charles J , Dutta, Sandipan , Kelly, William K , Russell, Carly ... - EAU - Eur Urol - 2018 Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Ryan, Charles J , Halabi, Susan , Ou, San-San , Vogelzang, Nicholas J ... - - Clin. Cancer Res. - 2007 Manuscript - Secondary-not-in-original - Primary - GU - CALGB-9583
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. Sandler, Robert S , Halabi, Susan , Baron, John A , Budinger, Susan ... - - N. Engl. J. Med. - 2003 Manuscript - Primary - Primary - GI - CALGB-9270
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). Small, Eric J , Halabi, Susan , Dawson, Nancy A , Stadler, Walter M ... - - J. Clin. Oncol. - 2004 Manuscript - Primary - Primary - GU - CALGB-9583
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance) Smith, Matthew R. , Halabi, Susan , Ryan, Charles J. , Hussain, Arif ... - - J. Clin. Oncol - 2014 Manuscript - Primary - Primary - GU - CALGB-90202
